Join us at the
Capital for Cures Summit
Thursday November 14, 4:00 PM
Take part in the innovation!
At the 2nd Capital for Cures summit, we will explore the evolving biotech and healthcare investment landscape in light of significant market shifts. With the US election outcomes and new European Commission mandates shaping the future of M&A, IPOs, and venture capital strategies, it is more crucial than ever to understand the implications for investors. This summit will focus on critical issues such as the acceleration of deal structures, the future of fundraising, and how evolving market dynamics influence business growth and investment decisions. Join us as we look ahead to 2025, providing actionable insights and fostering high-value connections in the biotech and healthcare sectors.
Capital For Cures
The Capital for Cures event is structured to critically assess the biotech and healthcare investment landscape, setting the stage for emerging trends in 2025. The event will explore pivotal topics such as the state of market recovery, the acceleration of IPOs and M&A activity, and how shifting investor attitudes are impacting deal structures. A key focus will be on the strategies venture capital firms are adopting in response to evolving market dynamics. With an emphasis on networking, this event will foster valuable connections among participants in a relaxed yet insightful setting.
Event Theme
Capital for Cures
Preliminary draft agenda
16:00 – 16:30
Open doors and registration
16:30 – 16:40
Welcome and introduction
Welcome by host (Slate Mountains Capital)
16:40 – 17:00
Keynote: Acquisition vs. In-Licensing and Capital Deployment
Discussing Strategies, analyzing the impact of strategic decisions on company growth and how venture capital and private equity firms navigate biotech investments.
17:00 – 17:20
Strategic Growth in Pharma: Navigating Acquisitions, In-Licensing, and Capital Deployment
A moderated 3-person panel featuring industry experts discussing M&A as a tool for transformation and portfolio management as well as trends for partnerships in biosimilars / biopharma
17:20 – 19:00
Networking and closing remarks
Capital For Cures
Event Highlights
Investor-focused keynote session
Emerging trends and investment strategies
Fireside chat on investment landscape
Expert analysis of funding challenges and opportunities
Exclusive networking:
Facilitating connections between participants and investors
Our speakers
Dr. Bodo Alexander Marr is Vice President, Head of M&A Treasury at MorphoSys AG. His
previous roles included Group Director M&A at APCOA Parking Holdings GmbH, Executive
Director Acquisition at Vonovia SE and Vice President at Hudson Advisors/Lone Star. He
earned his MBA from the HH Leipzig Graduate School of Management.
Keynote speaker: Dr. Bodo Alexander Marr
Key panelists
Roby Kanichavy is the Head of Technologies and Externalizations, Global Business Development and Alliance Management at Merck KGaA, Darmstadt, Germany. His team is responsible for bringing in innovative technologies that help the Merck R&D organization develop first-in-class and best-in-class therapeutic agents as well as externalization of deprioritized assets.
His business development experience spans venture capital, R&D and commercial partnerships as well as M&A transactions.
Roby Kanichavy
Tobias Goetz is Director, Corporate Development / M&A at Fresenius. His previous roles included various Investment Banking positions at Société Générale, Credit Suisse as well as Commerzbank. He holds a Master in Finance from UCD Michael Smurfit Graduate Business School.
Tobias Goetz
Roland Petrenkó is the Sector Head for Pharmaceutical, Healthcare & Life Science at SS&C Intralinks, a leading provider of secure collaboration tools and virtual data rooms (VDRs). Prior to joining SS&C Intralinks, he built a successful career in investment banking, working for prestigious institutions like Clairfield International, Raiffeisen Bank International, Erste Group Bank, and UniCredit. This experience equipped him with a deep understanding of transactions across multiple industries.
Roland Petrenko
Sebastian Gensior is the founder of Slate Mountains Capital, focused on helping companies in the healthcare and biotech sectors scale and connect with strategic investors. With a strong background in venture capital and market access, he also launched Capital for Cures, a growing network dedicated to fostering partnerships and innovation in healthcare. His goal is to create impactful opportunities for both startups and investors, driving the future of healthcare through collaboration.